Cost per Responder Analysis of Guselkumab Versus Certolizumab Pegol Using Efficacy Results from Pivotal Clinical Trials in Patients with Moderate to Severe Plaque Psoriasis
A Teeple, E Muser
Abstract not available.
Disclosures: Study sponsored by Janssen.
Copyright 2018 SKIN
Abstract - 54 Poster PDF - 10
- There are currently no refbacks.